Zidovudine nanoparticles - Onxeo

Drug Profile

Zidovudine nanoparticles - Onxeo

Alternative Names: Zidovudine-Transdrug

Latest Information Update: 04 Sep 2014

Price : $50

At a glance

  • Originator BioAlliance Pharma
  • Developer Onxeo SA
  • Class Antiretrovirals; Azides; Nucleosides; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors; Nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 04 Sep 2014 Discontinued - Preclinical for HIV infections in France (PO)
  • 21 Feb 2007 Preclinical development is ongoing
  • 28 May 2005 Preclinical trials in HIV infections treatment in France (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top